What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2021-03-31 compared with 2020-03-30 · 27 added, 21 removed, 2 unchanged (96% of the section changed)

Legal Proceedings.

an action against BioLife in December of 2017 for Breach of Contract.

The amount of damages we are seeking in this matter are

yet to be determined.

commenced an action against BioLife in December of 2017 for Breach of Contract.

The amount of damages we are seeking

in this matter have yet to be determined.

Damages are not covered by insurance.

BioLife, the defendant, has filed its Answer, Affirmative Defenses

and a Counterclaim in the amount of $96,676 representing the Invoices withheld after BioLife indicated that they were not intending

to fulfill the balance of the contract.

BioLife, the defendant, has filed its Answer,

Affirmative Defenses and a Counterclaim in the amount of $96,676 representing the invoices withheld after BioLife indicated that

they were not intending to fulfill the balance of the contract.

We have denied the allegations of the counterclaim.

We conducted one mediation session

to date but were unable to resolve the matter.

The parties are currently engaged in discovery leading to an anticipated trial

date in or after September 30, 2020, which date may be adjusted further as a consequence of the closing of the Courts in connection

with the declared state of emergency caused by the Covid-19 pandemic.

Although it cannot be determined, we believe there is

little chance for an unfavorable outcome in this matter.

In our only other legal

matter in 2019, we resolved all remaining claims with our insurance carrier for Business Interruption losses and Extended Business

Interruption losses arising from flood damage which occurred at our New Brunswick facility on January 5, 2016.

The outstanding

matters under the insurance policies were compromised and settled on terms agreeable to the parties.

Mine Safety Disclosures.

Not Applicable.

one mediation session to date but have been unable to resolve the matter.

The parties are currently waiting to start discovery,

which we believe will lead to an anticipated trial date.

The scheduled dates for these events to transpire have yet to be determined,

as they are dependent on the reopening of the Courts, which have been temporarily closed in connection with the declared state

of emergency caused by the COVID-19 pandemic.

Although it cannot be determined, we believe there is little chance for an unfavorable

outcome in this matter.

2019, we resolved the claim with our insurance carrier for Business Interruption losses and Extended Business Interruption losses

arising from flood damage which occurred at our New Brunswick facility on January 5, 2016.

The outstanding matters under the insurance

policies were compromised and settled on terms agreeable to the parties.

October 20, 2020, the Company received correspondence from counsel in Scotland U.K.

advising of their representation of Symbiosis

Pharmaceutical Services Limited in connection with Symbiosis’

claim that it is owed £110,250.00 (US $152,145.00).

The Company denies that any monies are due and owing and the Company has engaged counsel in Scotland to further represent its

No judgment can be made as to the likelihood of an unfavorable outcome should a claim be asserted however the Company

believes and has been advised that it has meritorious defenses and positions which the Company intends to vigorously assert in

the event of the formal assertion of a claim.

Safety Disclosures.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings